{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:12:48Z","timestamp":1788250368178,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jcf.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:12:39Z","timestamp":1720915959000},"page":"853-856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-8257","authenticated-orcid":false,"given":"Anjali","family":"Santhakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Pickles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Winterbottom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Beynon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Tofeec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-4431","authenticated-orcid":false,"given":"P","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.06.007_bib0001","article-title":"Cystic fibrosis-related diabetes: prevalence, screening, and diagnosis","volume":"27","author":"Khare","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2024.06.007_bib0002","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.06.007_bib0003","first-page":"23","article-title":"Cystic fibrosis related diabetes (CFRD) in the era of modulators: a scoping review","volume":"46","author":"Prentice","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2024.06.007_bib0004","doi-asserted-by":"crossref","unstructured":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents 23, 8 December 2022 1212\u201328.","DOI":"10.1111\/pedi.13453"},{"issue":"12","key":"10.1016\/j.jcf.2024.06.007_bib0005","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Sitagliptin Study 021 Group . Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jcf.2024.06.007_bib0006","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Sitagliptin Study 020 Group . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.007_bib0007","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"issue":"42","key":"10.1016\/j.jcf.2024.06.007_bib0008","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"1","author":"Battelino","year":"2019","journal-title":"Diab Care"},{"key":"10.1016\/j.jcf.2024.06.007_bib0009","volume":"9","year":"2023"},{"key":"10.1016\/j.jcf.2024.06.007_bib0010","article-title":"The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes","volume":"27","author":"Hasan","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.007_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s005920050116","article-title":"Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective","volume":"35","author":"Nauck","year":"1998","journal-title":"Acta Diabetol"},{"issue":"5","key":"10.1016\/j.jcf.2024.06.007_bib0011","doi-asserted-by":"crossref","first-page":"E851","DOI":"10.1210\/jc.2010-2460","article-title":"Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis\u2014Effects of pancreatic enzyme supplementation","volume":"96","author":"Kuo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.007_bib0012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2011.11.001","article-title":"Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus","volume":"11","author":"Hillman","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2024.06.007_bib0013","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1210\/jc.2013-4417","article-title":"Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial","volume":"99","author":"Perano","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.jcf.2024.06.007_bib0014","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of Sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.007_bib0015","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.jcf.2021.02.005","article-title":"Chronic incretin-based therapy in cystic fibrosis-related diabetes: a tale of 3 patients treated with sitagliptin for over 5 years","volume":"20","author":"Olatunbosun","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.06.007_bib0016","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1055\/s-2007-985157","article-title":"Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes","volume":"39","author":"Colette","year":"2007","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.jcf.2024.06.007_bib0017","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1515\/cclm-2018-0220","article-title":"The correlation between glucose fluctuation from self-monitored blood glucose and the major adverse cardiac events in diabetic patients with acute coronary syndrome during a 6-month follow-up by WeChat application","volume":"56","author":"Xia","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"issue":"2","key":"10.1016\/j.jcf.2024.06.007_bib0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2337\/dc09-1492","article-title":"Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain","volume":"33","author":"Hameed","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.007_bib0019","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","article-title":"Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline","volume":"17","author":"Chan","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.007_bib0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2016.02.005","article-title":"Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.007_bib0021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/diacare.23.1.126b","article-title":"HbA1c is not recommended as a screening test for diabetes in cystic fibrosis","volume":"23","author":"Holl","year":"2000","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.007_bib0022","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcf.2016.02.012","article-title":"Hypoglycaemia in cystic fibrosis in the absence of diabetes: a systematic review","volume":"15","author":"Armaghanian","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.06.007_bib0023","article-title":"Spontaneous and iatrogenic hypoglycemia in cystic fibrosis","volume":"26","author":"Hicks","year":"2021","journal-title":"J Clin Transl Endocrinol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:12:54Z","timestamp":1788246774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324007768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1569199324007768"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.06.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}